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Abstract
Introduction The receptor ErbB3/HER3  is often over-
expressed in human breast cancers, frequently in conjunction
with over-expression of the proto-oncogene ERBB2/HER2/
NEU. Although the prognostic/predictive value of ErbB3
expression in breast cancer is unclear, ErbB3 is known to
contribute to therapeutic resistance. Understanding ErbB3
functions in the normal mammary gland will help to explain its
role in cancer etiology and as a modulator of signaling
responses to the mammary oncogene ERBB2.
Methods To investigate the roles of ErbB3 in mouse mammary
gland development, we transplanted mammary buds from
ErbB3-/- embryos into the cleared mammary fat pads of wild-type
immunocompromised mice. Effects on ductal outgrowth were
analyzed at 4 weeks, 7 weeks and 20 weeks after
transplantation for total ductal outgrowth, branch density, and
number and area of terminal end buds. Sections of glands
containing terminal end buds were analyzed for number and
epithelial area of terminal end buds. Terminal end buds were
also analyzed for presence of mitotic figures, apoptotic figures,
BrdU incorporation, and expression of E-cadherin, P-cadherin,
α-smooth muscle actin, and cleaved caspase-3.
Results The mammary ductal trees developed from ErbB3-/-
buds only partly filled the mammary fat pad. In contrast to similar
experiments with ErbB2-/- mammary buds, this phenotype was
maintained through adulthood, pregnancy, and parturition. In
addition, and in contrast to similar work with ErbB4-/- mammary
buds, lobuloalveolar development of ErbB3-/-  transplanted
glands was normal. The ErbB3-/- mammary outgrowth defect
was associated with a decrease in the size of the terminal end
buds, and with increases in branch density, in the number of
terminal end buds, and in the number of luminal spaces.
Proliferation rates were not affected by the lack of ErbB3, but
there was an increase in apoptosis in ErbB3-/- terminal end
buds.
Conclusions Endogenous ErbB3 regulates morphogenesis of
mammary epithelium.
Introduction
The epidermal growth factor receptor (EGFR) family of recep-
tor tyrosine kinases, which consists of EGFR, ErbB2, ErbB3,
and ErbB4, is important in many normal developmental proc-
esses and is often over-expressed or mutated in human cancer
(for review, see [1]). Ligand binding stimulates homodimeriza-
tion and heterodimerization of EGFR family members. The
dimerization facilitates cross-phosphorylation of tyrosines
within the cytoplasmic domains that become binding sites for
downstream effector proteins. The proto-oncogene product
ErbB2 is unique in that it does not bind soluble ligands and
requires a heterodimer partner for ligand-dependent activa-
tion. ErbB3 is also unique because the kinase domain is cata-
lytically inactive, so that ErbB3 also requires a
BrdU: 5-bromo-2-deoxyuridine; EGFR: epidermal growth factor receptor; H&E: hematoxylin and eosin; IHC: immunohistochemistry; MMP: matrix met-
alloproteinase; NRG: neuregulin; NSCLC: non-small-cell lung carcinoma; PI3K: phosphatidylinositol 3'-kinase; SD: standard deviation; SMA: α-
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heterodimerization partner for activity. Once activated, ErbB3
is strongly linked to prosurvival signaling through the phos-
phatidylinositol 3'-kinase (PI3K)/Akt pathway. ErbB3 has six
binding sites for the p85 adaptor subunit of PI3K. PI3K cata-
lyzes formation of 3' phosphoinositides that recruit the protein
kinase Akt/protein kinase B to the membrane for activation by
phosphorylation. The activated Akt is involved in cellular proc-
esses including survival, cell growth, and proliferation (for
review, see [2]).
The ErbB2/ErbB3 heterodimer, one of many possible ErbB
heterodimer combinations, is important in tumorigenesis [3-6]
(for review, see [7]). ErbB3 is a preferred heterodimerization
partner for the proto-oncogene ErbB2, and the ErbB2/ErbB3
heterodimer is highly biologically active and pro-tumorigenic in
vitro [8]. ErbB2 and ErbB3 are often co-over-expressed in
breast, ovarian, colorectal, and bladder cancers [9-13].
Recent advances in the treatment of cancers driven by ErbB
alterations include the use of small molecule tyrosine kinase
inhibitors and antagonist antibodies [14]. Surprisingly, ErbB3
signaling is often crucial to the success or failure of ErbB tyro-
sine kinase inhibitors, despite the lack of intrinsic ErbB3
kinase activity. In breast cancers with amplified ERBB2,
ErbB3 augments ErbB2 signaling through strong coupling to
survival pathways that complement the signals emanating from
ErbB2, thus allowing the cancer cells to escape from inhibition
therapy [15]. In all likelihood, ErbB3 signaling will also contrib-
ute to resistance to single and dual specificity EGFR and
ErbB2 inhibitors (for example, lapatinib) [16], as they come
into clinical use for trastuzumab-resistant  ERBB2-amplified
breast cancer, and to pertuzumab, an antibody inhibitor of
ErbB2/ErbB3 heterodimerization [17]. In non-small-cell lung
carcinoma (NSCLC) cells with mutated EGFR, amplification of
the  MET  oncogene activates prosurvival ErbB3 signaling,
which allows escape from tyrosine kinase inhibition [18] (for
review, see [19]). Given these findings, downregulation of
ErbB3 signaling in human cancers is critical to successful
ErbB-targeted tyrosine kinase inhibitor therapy.
The importance of ErbBs in human breast cancer is linked to
their importance in normal mammary gland biology. Under-
standing these normal functions and their regulators will lead
to better prognostication and treatment decisions, and to iden-
tification of novel therapeutic targets. However, the individual
role played by each receptor in mammary gland development
has been difficult to determine. This is because the individual
receptors and their agonists display complex and overlapping
expression patterns, and because the receptors are required
for multiple developmental activities, some of which are essen-
tial for prenatal viability [20,21]. Both EGFR and ErbB2 are
highly expressed and co-localized in all major cell types in the
pubescent mouse mammary gland, but at maturity they are dif-
ferentially localized, with EGFR in the stroma and ErbB2 in the
epithelium [20]. ErbB3 and ErbB4 are only expressed at low
levels in postpubescent mammary glands from virgin mice, but
they are expressed at higher levels during pregnancy and lac-
tation [20,22]. All four of the ErbBs are expressed in the late
pregnancy and early lactation glands. This differential expres-
sion pattern implies important roles for EGFR and ErbB2 in the
developing mammary gland, and for ErbB3 and ErbB4 in the
later stages of mammary gland development and differentia-
tion.
Early studies suggested that only ErbBs EGFR and ErbB2 are
important in early postnatal mammary development, because
ErbB3 and ErbB4 are expressed at very low levels, and
because neuregulins (NRGs), growth factors that bind exclu-
sively to ErbB3 and ErbB4, were difficult to detect at early
stages [20]. Nonetheless, there is evidence for ErbB3 or
ErbB4 signaling in the pubescent mammary gland. Implanta-
tion of Elvax ethylene vinyl acetate (Elvax Ethylene, Dupont,
Wilmington, Delaware, USA) slow release pellets containing
NRG1, normally expressed during pregnancy, promoted duc-
tal growth and alveologenesis in mammary glands of pubes-
cent mice [23]. Because NRG1 binds ErbB3 and ErbB4 but
not EGFR or ErbB2, this suggested that ErbB3 and/or ErbB4
are functional (but not necessarily active) at puberty. ErbB4
null mice, with the essential cardiac function supplied by trans-
gene-driven expression of ErbB4 cDNA exclusively in the
heart, survive past birth and are defective in lactation, but
undergo normal development at puberty [24]. This indicates
that ErbB4 is not essential during pubescent mammary gland
development, and implies, by elimination, that ErbB3 is the
active receptor in NRG1 implantation experiments.
Attempts to determine the role of ErbB3 in mammary gland
development have been impeded by the embryonic lethality
caused by ErbB3 gene disruption, which leads to cardiac and
neurodevelopmental defects [25]. To determine the roles
played by ErbB3 in mammary gland development, we chose to
use a loss-of-function approach. Mammary buds isolated from
ErbB3 null embryos at day 12.5 were transplanted into the
cleared fat pad of prepubescent immunocompromised recipi-
ent mice. Transplanted ErbB3 null buds supported growth of
an epithelial tree, but the ducts did not penetrate the fat pad
to the same extent as ducts from a wild-type bud transplant.
Also, the terminal end buds (TEBs) that pilot ductal extension




A null mutation was created at the ErbB3  gene locus by
homologous recombination resulting in the deletion of amino
acids 73 to 107. This results in embryonic lethality as early as
day 13.5 [25]. Embryonic day 12.5 embryos (stage estimated
from timed pregnancies) resulting from an intercross of
ErbB3+/- heterozygotes in a mixed 129/C57BL6/BalbC or a
high C57BL6 strain background were harvested by Caesar-Available online http://breast-cancer-research.com/content/10/6/R96
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ean section. Immunoblot analysis of ErbB3+/+, ErbB3+/-, and
ErbB3-/-  embryos verified dose-dependent expression of
ErbB3 (Additional data file 1). Mammary gland transplants
were performed as described in [26]. For each recipient
mouse, one number four inguinal mammary fat pad was trans-
planted with a single mammary bud isolated from a ErbB3-/-
female, and the contralateral number four inguinal fat pad was
transplanted with a mammary bud from an ErbB3+/+  or
ErbB3+/- female littermate. The fat pads containing transplants
were harvested from virgin hosts at 4, 7, or 20 weeks after
transplantation, or the recipients were bred and the glands
harvested at 1 day postpartum. The overall take rate for trans-
planted buds was 74% and was not affected by the genotype
of the donor embryo. All animal work was approved by the Yale
University Institutional Animal Care and Use Committee and
followed internationally recognized guidelines.
Morphological analysis
Whole mount analysis was carried out as described in [23,26].
Four +/+ and four -/- gland whole mounts of outgrowths were
analyzed at 4 weeks after transplantation; three +/+, six +/-
and five -/- glands 7 weeks after transplantation; one +/+, one
+/- and two -/- glands at 20 weeks after transplantation; four
+/- and five -/- glands at 1 day postpartum, after the first preg-
nancy; and one +/+ and one -/- at 1 day postpartum, after the
second pregnancy.
Histological analysis was performed as described in [26,27].
Five +/+, three +/-, and seven -/- gland outgrowths were ana-
lyzed 4 weeks after transplant; three +/+ or +/- and three -/-
glands at 7 weeks after transplant; one +/+ and two -/- glands
at 20 weeks after transplantation; three +/- and four -/- glands
at 1 day postpartum, after the first pregnancy; and two +/+ or
+/- and two -/- 1 day postpartum, after the second pregnancy.
Measurements of total ductal outgrowth length on whole
glands (no half glands) and branch density (whole and half
glands) were taken as described in [26], except with the use
of ImageJ imaging software (Wayne Rasband, National Insti-
tutes of Health, Bethesda, Maryland, USA). Briefly, the total
ductal outgrowth in digital images of glands was determined
by drawing a line from the one edge of furthest ductal out-
growth to the opposite edge of furthest ductal outgrowth, and
measuring the length of that line in arbitrary units. This analysis
was done in triplicate for each gland and the average measure-
ment is reported. The branchpoint analysis was done by count-
ing the number of branchpoints within a box of fixed
dimensions. The area of TEBs in digital images of carmine
alum-stained whole mounted glands was determined by outlin-
ing the TEB using the elliptical or freehand selection tool in
ImageJ imaging software. The epithelial area of the TEBs in the
sections from paraffin-embedded glands were analyzed simi-
larly, but areas of luminal and other vacuolated spaces were
subtracted from the outer measurements to give the epithelial
area only.
Immunohistochemistry
Immunohistochemistry (IHC) for E-cadherin, P-cadherin, α-
smooth muscle actin (SMA) were performed as described by
Jackson-Fisher and coworkers [26], except a 1:200 dilution of
primary antibody was used for SMA IHC. For E-cadherin IHC,
seven +/+, four +/-, and 10 -/- glands were analyzed; and for
SMA IHC six +/+, four +/-, and 10 -/- glands were analyzed.
Mouse IgG was used as a negative control for both E-cadherin
and SMA IHC. For P-cadherin IHC, seven +/+, four +/-, and
10 -/- glands were analyzed and goat IgG was used as a neg-
ative control.
BrdU and cleaved caspase 3
5-Bromo-2-deoxyuridine (BrdU) analysis (n = 3 +/+, 1 +/-, and
6 -/-) was performed as described previously [26,28]. For
cleaved caspase 3 IHC (n = 5 +/+, 3 +/-, and 7 -/- glands),
rabbit polyclonal cleaved caspase-3 (Asp175) antibody (Cell
Signaling Technology, Danvers, MA, USA) was used. The anti-
gen was unmasked in a low pH citrate buffer under heat and
pressure. The antibody was diluted 1:100 in Primary Antibody
Diluting Buffer (Biomeda, Foster City, CA, USA), overnight at
4°C. Endogenous peroxidases were inactivated with 1%
hydrogen peroxide 10 minutes, and a 1:100 diluted bioti-
nylated anti-rabbit secondary antibody solution (Vectastain
Elite ABC kit, PK-6101; Vector Laboratories, Burlingame, CA,
USA) was added. Peroxidase activity was detected with
freshly prepared DAB solution (Biogenex, San Ramon, CA,
USA).
Histological analysis of apoptosis
In a double-blind analysis, five TEBs on each hematoxylin and
eosin (H&E) stained section were scored for total number of
nuclei and for the number of apoptotic cells (n = 6 +/+ or +/-
, and 7 -/- glands; 25 slides total). Slides were examined using
an Axioskop microscope (Carl Zeiss Microimaging, Thorn-
wood, NJ, USA). Mammary bud epithelial cell nuclei and apop-
totic cells within a 100 square (1 mm × 1 mm) grid were
counted manually on a laboratory counter (Denominator,
Woodbury, CT, USA). Five separate mammary buds were
counted for one tissue section per slide at 40×. The ratio of
apoptotic cells to nuclei was determined.
Results
Analysis of ErbB3 function in postnatal development of the
mammary gland has been hampered by the embryonic lethality
of ErbB3 knockout mice. ErbB3-/- null mice die in utero at day
13.5 or as late as days 16 to 18, depending on the strain back-
ground, because of cardiac cushion abnormalities [25]. How-
ever, postnatal development of ErbB3-/- epithelium in ErbB3
wild-type stroma can be analyzed by transplantation. Mam-
mary buds from day 12.5 ErbB3-/- embryos were isolated and
transplanted into prepubescent immunocompromised recipi-
ent mammary fat pads that had been surgically cleared of the
endogenous epithelium. The contralateral gland of each recip-
ient mouse was also cleared of epithelium and transplantedBreast Cancer Research    Vol 10 No 6    Jackson-Fisher et al.
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with an ErbB3 wild type (+/+) or heterozygous (+/-) mammary
bud from a female littermate embryo as a positive control. At
various times after transplantation, the transplanted glands
were harvested from the recipient mice and the epithelial tree
was visualized by carmine alum staining of whole mounted
glands.
At 4 weeks after transplantation the epithelial trees resulting
from ErbB3+ (+/+ or +/-) transplant had filled a majority of the
fat pad (Figures 1a and 2a), whereas the ErbB-/- transplant epi-
thelial trees only filled a small fraction of the glands (Figures 1b
and 2a). The total ductal length was measured for each of the
paired contralateral gland outgrowths (four pairs). The length
of the ErbB3+ outgrowths and the severity of the ErbB3-/- pen-
etration defect varied at 4 weeks (Figure 2a). The mean
ErbB3+ outgrowth length was 412; the mean ErbB3-/- out-
growth was 140. At seven weeks after transplantation, most of
the ErbB3+ outgrowths (eight glands) had completely filled
the fat pad (Figures 1c and 2b), but none of the ErbB3-/- out-
growths (five glands) filled the fat pad (Figures 1d and 2b).
The severity of the ErbB3-/- ductal penetration defects varied.
At 7 weeks, transplantation yielded two 'paired' glands from
mice in which both ErbB3+ and ErbB3-/- transplants were suc-
cessful. For these pairs only, the mean ErbB3+ outgrowth
length was 721; the mean ErbB3-/- outgrowth was 528 (Figure
2b). For all of the glands assayed, including a number of
'unpaired' glands from mice in which only one of the two trans-
plants survived, the mean ErbB3+ outgrowth length was 737;
the mean ErbB3-/- outgrowth was 406. This ductal penetration
defect persisted in adult nonparous ErbB3-/-  glands (two
glands; Figures 1f and 2e), and was not rescued by the influ-
ence of hormones during pregnancy or lactation (Figure 1h
and 2e). ErbB3+ outgrowths (four glands) filled the fat pad and
normal alveolar structures were evident at 1 day postpartum
(Figures 1g and 2e). Even though the ErbB3-/- outgrowth did
not reach the edges of the fat pad, normal alveolar structures
were present at 1 day postpartum (Figures 1h and 2e; four
ErbB3+ glands and four ErbB3-/- glands). On the histological
level, the alveoli were distended, with milk in the lumens and
lipid droplets in the cells, suggesting that both the differentia-
tion and secretory pathways are normal in the +/+ and -/-
glands (insets, Figure 1g,h). Analysis of lactation after 1 day
postpartum is not possible because the epithelial outgrowth
Figure 1
Whole mount analysis of ductal morphogenesis in transplanted glands Whole mount analysis of ductal morphogenesis in transplanted glands. Mammary buds from ErbB3+/+ or ErbB3+/- and ErbB3-/- day 12.5 embryos 
were transplanted into contralateral cleared mammary fat pads of 3-week-old Rag1-/- females. The glands were harvested at (a, b) 4 weeks, (c, d) 7 
weeks, (e, f) 20 weeks after transplantation, or (g, h) 1 day postpartum. Shown are paired contralateral transplanted glands from the same recipient 
mouse. The 20-week glands were from a mouse that was mated but did not deliver a litter and was not pregnant at time of sacrifice. The 1 day post-
partum (1D PP) mouse was mated about 8 weeks after transplantation and a litter was delivered about 12 weeks after transplantation. The glands 
were harvested 1D PP. Inserts in panels g and h are hematoxylin and eosin stained sections of +/+ (panel g) and -/- (panel h) paired transplants at 
1D PP.Available online http://breast-cancer-research.com/content/10/6/R96
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from the transplant is not attached to the nipple, so remodeling
of the gland to the prepregnancy state occurs quite rapidly.
In addition to the ductal penetration defect, there was an
increase in the number of branchpoints in the ErbB3-/- out-
growths in comparison to the ErbB+ outgrowths (Figure 2c,d).
Likewise, there was an increase in the number of TEBs in
ErbB3-/-  glands (Figure 3a). TEBs are bulbous structures
found at the invasive ends of an advancing ducts, and are
major sites of proliferation and apoptosis in the pubescent
mammary gland [29]. Normally, TEBs regress once the devel-
oping epithelial tree has reached the edge of the fat pad. At 4
weeks after transplantation, several large TEBs are evident in
whole mounts of ErbB3+ outgrowths (Figure 3a, top left). how-
ever, by 7 weeks after transplantation (Figure 3a, middle left)
the TEBs have mainly regressed and they are not present at 20
weeks after transplantation (Figure 3a, bottom left). TEBs are
visible in ErbB3-/- glands at 4 weeks (Figure 3a, top right) and
at 7 weeks (Figure 3a, middle right). Interestingly, they have
regressed by 20 weeks after transplantation (Figure 3a, bot-
Figure 2
Analysis of epithelial outgrowth Analysis of epithelial outgrowth. Diamonds represent the average end to end length of total ductal outgrowth measured in arbitrary units in a trans-
planted gland at (a) 4 weeks and (b) 7 weeks for the null and wild-type or heterozygous (Wt/het) donor genotypes. The average numbers of branch-
points within a unit area are shown for (c) 4 weeks and (d) 7 weeks after transplantation. (e) Ductal outgrowths for 20 weeks after transplantation, 
mid-pregnancy, and 1 day postpartum (1D PP) are shown together. In all panels, solid lines connect the null with the Wt/het pair of contralateral 
transplants from the same recipient mouse. Dotted lines connect the mean of the outgrowths from contralateral glands in complete null-Wt/het pairs, 
and the mean lengths are listed at the termini of these lines. Asterisks represent the mean from all recipients of a given genotype, with mean lengths 
presented in italics in panels b and d.Breast Cancer Research    Vol 10 No 6    Jackson-Fisher et al.
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Figure 3
Whole mount analysis of TEBs Whole mount analysis of TEBs. (a) High-magnification TEBs in carmine alum stained whole mounts. Large bulbous TEBs are present at the end of 
the advancing duct in +/+,+/- glands at 4 weeks after transplantation (top left), but have regressed by 7 weeks (middle left) and 20 weeks (bottom 
left) after transplantation. The TEBs in the -/- glands are present at 4 weeks (top right), they persist at 7 weeks (middle right), and have regressed by 
20 weeks (bottom right). Whole mounts at a given time point are contralateral glands from the same recipient mouse at the same magnification. (b) 
Number and area of TEBs after transplantation. Shown are the number of TEBs in a carmine alum (CA)-stained whole mount (top left) and the aver-
age epithelial area of the TEBs (top right) at 4 weeks after transplantation in three mice with paired contralateral outgrowth; and the number of TEBs 
(bottom left) and the epithelial area of the TEB in stained paraffin-embedded sections (bottom right) at 4 weeks aftertransplantation in six ErbB3-/- 
glands and six ErbB3+ glands, two of which are paired contralateral outgrowths. Solid lines connect the paired null and wild-type or heterozygous 
(wt/het) contralateral transplants from the same recipient mouse. Dotted lines connect the mean of the outgrowths from contralateral glands in the 
complete null-wt/het pairs, and the means are listed at the termini of these lines. Asterisks represent the mean from all recipients of a given genotype, 
with means listed in italics. Circles mark the TEBs shown in panel c. (c) Representative TEBs in paraffin-embedded sections. An ErbB3+ TEB (bot-
tom right) in an hematoxylin and eosin stained paraffin-embedded section compared with a ErbB3-/- TEB (bottom left) taken at the same magnifica-
tion. Both TEBs were near average size for the respective genotype. Circles in panel b, lower right, mark the corresponding diamonds. TEB, terminal 
end bud.Available online http://breast-cancer-research.com/content/10/6/R96
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tom right), despite the incomplete extension through the fat
pad. The number of TEBs visible in both carmine alum stained
whole mounted glands (Figure 3b, top left) and across a series
of sections from paraffin-embedded whole glands (Figure 3b,
bottom right) was greater in ErbB3-/- glands than in ErbB3+
glands. However the epithelial area of the TEBs was smaller
for the ErbB3-/- glands than for the ErbB3+ glands. This was
observed in both the carmine alum stained whole mounts (Fig-
ure 3b, top right) and in the sections from the paraffin-embed-
ded glands (Figure 3b, bottom right). TEBs from ErbB3+
glands were larger in size and epithelial area (Figure 3c, right)
than TEBs from ErbB3-/- glands (Figure 3c, left); the corre-
sponding glands are marked with circles in Figure 3b (lower
right). In the carmine alum analysis (three pairs), the mean area
of the ErbB3+ TEBs was 631 whereas the mean area of the
ErbB3-/- TEBs was 221. In an analysis of the paraffin sections,
the mean area of the ErbB3+ TEBs (six glands) was 668,
whereas the mean area of the ErbB3-/- TEBs (six glands) was
443. In analysis of only the paired paraffin sections (two pairs),
the mean area of the ErbB3+ TEBs was 734 whereas the
mean area of the ErbB3-/- TEBs was 395.
A cross-section of a classical TEB reveals two distinct epithe-
lial cell layers. The outer layer of cap cells at the advancing end
of the buds merges into the more distal myoepithelial layer
[30,31]. Cap cells are active sites for proliferation in the TEB
and the progenitors for the myoepithelial cells that line the duct
and the interior body and luminal cells. The second layer
encompasses the inner, multilayered body cells that line the
lumen and are thought to be major sites of apoptosis in TEBs
[32,33]. Both of these cell types are apparent in ErbB3+/+
TEBs at 4 weeks after transplantation (Figure 4a). The single
Figure 4
Immunohistochemical analysis of a TEB in serial sections Immunohistochemical analysis of a TEB in serial sections. (a-d) TEBs from serial sections of an ErbB3+/+ gland 4 weeks after transplantation (panels 
a-d) have a typical single layer cap cell/myoepithelial cell outer layer (panels b and d) and a multilayered body cell section (panel c). (e-i, j-n, and o-
s) Serial sections of three representative -/- TEBs at 4 weeks after transplantation. The three TEBs vary in the cap cell layer (panels h, l, and q), in the 
layers in the body cell layer (panels g, m, and d), and in the size of the spaces between the cap and body cell layers (panels i, j, and o). (t-w) The mul-
tilayered cap cell compartment has large spaces and the body cell layer is a single layer in the serial section of an ErbB3-/- TEB from a 7-week post-
transplantation gland. cc3, cleaved caspase 3; H&E, hematoxylin and eosin; IgG, negative control antibody; E-cad, E-cadherin; P-cad, P-cadherin; 
SMA, smooth muscle actin; TEB, terminal end bud.Breast Cancer Research    Vol 10 No 6    Jackson-Fisher et al.
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layer of cap (and myoepithelial) cells is marked by expression
of SMA and the adhesion molecule P-cadherin (Figure 4b,d),
whereas multilayered body cells express the adhesion mole-
cule E-cadherin (Figure 4c) [34,35]. There is a large lumen
surrounded by the body cells in each of the consecutive
stained sections from the ErbB3+/+ gland. The ErbB3-/- TEBs
have the same general organization, but they differ in the type
and severity of the defect (Figure 4, bottom four rows). The
first ErbB3-/- TEB (Figure 4e–i) has a single layer of cap cells
(Figure 4h) and a multilayered body cell compartment (Figure
4g); however, there are large vacuolated spaces between and
the cap and body cell layers. The second ErbB3-/- TEB (Figure
4j–n) also has some spaces between the cap and body cell
layers, and the lumen is filled with cells. There is an influx of
cells that express smooth muscle actin in the body cell com-
partment (Figure 4l) and do not express E-cadherin like the
surrounding body cells (figure 4m). In a more severely defec-
tive ErbB3-/- TEB (Figure 4o–s), there are fewer body cells.
There is a single layer of cap cells surrounding a large space
(Figure 4q), and few body cells (Figure 4p) that surround a
small luminal space. Although the three 4-week TEBs in Figure
4 are from different mice, each of these three types of ErbB3-
/- TEB defects can be found in the same gland and in glands
from different mice. The 7-week ErbB3-/- TEB (Figure 4t–w) is
disorganized in that there is a multilayered SMA-positive cap/
myoepithelial cell compartment, with large spaces with the lay-
ers (Figure 4u). The normally multilayered body cells are a sin-
gle layer surrounding a small lumen (Figure 4v).
The TEB is the major site of proliferation and apoptosis in the
developing mammary gland. The proximal cap cells are actively
proliferating cells, whereas the body cells that line the duct
undergo apoptosis to clear the lumen during growth of the
duct [32,33]. A decrease in proliferation or an increase in
apoptosis could result in the ductal penetration defect associ-
ated with ErbB3-/- transplants. Histological analysis of the H&E
stained ErbB3-/- TEBs revealed fragmented condensed nuclei
suggestive of apoptosis (Figure 5, top right) in comparison
with ErbB3+/+ TEBs (Figure 5, top left). Hence, we enumer-
ated apoptotic bodies in fields of H&E sections from ErbB3+
and ErbB3-/- mammary glands. Of the seven null glands ana-
lyzed, the mean number of apoptotic bodies was 2.3 (standard
deviation [SD] 2.0). Six wild-type or heterozygous glands had
a mean of 0.8 apoptotic bodies (SD 0.5). The counts were
also compared after normalization to the total number of epi-
thelial nuclei in each sample. Among all glands analyzed,
ErbB3-/- TEBs (seven glands) had a mean ratio of apoptotic
bodies to nuclei of 0.03 (SD 0.03), whereas ErbB3+ glands
(six glands) had a mean ratio of 0.01 (SD 0.01). In the four
pairs only, ErbB3-/- TEBs had a mean ratio of apoptotic cells to
nuclei of 0.02 (SD 0.01), whereas ErbB3+ glands had a mean
ratio of 0.01 (SD 0.01).
The area of the ErbB3-/- TEB with the most apoptotic nuclei
also displayed an increase in cleaved caspase 3 positive cells
(Figure 5). On average, ErbB3+/+ TEBs had 2.15% cleaved
caspase 3 positive cells, with a range of 0.4% to 5.4% posi-
tive. ErbB3-/- TEBs had an average of 6.3% cleaved caspase
3 positive cells, with a range of 1.6% to 18.5% positive. Over-
all, then, there was a trend for null TEBs to show more signs
of apoptosis, but the differences may not rise to the level of
statistical significance.
Proliferation was not affected by the loss of ErbB3. Immuno-
histological analysis of BrdU labeling yielded similar results for
ErbB3+ TEBs (29% BrdU positive) and ErbB3-/- TEBs (32%
BrdU positive; Figure 5, lower panels).
Discussion
Deletion of ErbB3 in the epithelium of the mouse mammary
gland resulted in reduced ductal outgrowth that was evident
at puberty, and endured through adolescence, pregnancy, and
early lactation, establishing that ErbB3 is absolutely required
in the epithelium during pubescent mammary gland develop-
ment. This phenotype is more severe than that induced by
knockout of any of the three other ErbBs in mammary epithe-
lium, underscoring the importance of ErbB3 in mammary
Figure 5
Apoptosis in TEBs Apoptosis in TEBs. H&E stained TEBs in +/+ transplanted glands (top 
left) have few apoptotic nuclei and one cleaved caspase 3 positive 
(brown stain) cell (middle left). H&E stained TEBs in -/- transplanted 
glands (top right) have numerous apoptotic nuclei and cleaved caspase 
3 positive cells (middle right). BrdU-positive cells (brown stain) are 
present in both the +/+ transplanted glands (bottom left) and in the -/- 
transplanted glands (bottom right). BrdU, 5-bromo-2-deoxyuridine; cc3, 
cleaved caspase 3; H&E, hematoxylin and eosin; TEB, terminal end 
bud.Available online http://breast-cancer-research.com/content/10/6/R96
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development. The postnatal requirement of ErbB3 in the
stroma was not addressed in this study. This ductal out-
growth/penetration phenotype varied in severity. Lobuloalveo-
lar development was not affected in ErbB3-null glands. Lack
of epithelial ErbB3 affected the phenotype of TEBs. TEBs
were more numerous but smaller in size in the ErbB3-/- out-
growths. Apoptotic cells were more common within the TEBs
in the null glands, but there was no apparent change in the
proliferative cells.
In related experiments, Qu and coworkers [36] inhibited
ErbB3 expression in the mammary gland by using Cre recom-
binase to invert a transcriptional suppressor integrated in an
intron. Mammary glands, analyzed at 4 weeks and 8 weeks,
had lower ductal density, fewer branches, and fewer TEBs.
TEB morphology was not discussed, and neither was develop-
ment at later time points. The limited analysis, the fact that the
experimental approach involved reduction, not elimination, of
ErbB3 expression, and other technical differences make it dif-
ficult to compare that report with the present study directly.
The pubescent epithelial outgrowth/penetration defect we
obtained was accompanied by an increase in the branch den-
sity in ErbB3-null glands. Mammary branching is modulated by
diverse factors, including members of the EGFR family (for
review, see [37]). The interaction between the ErbB family and
matrix metalloproteinases (MMPs), in particular, is known to be
important in branching. The EGFR promotes activation of
MMP-2 and MMP-14, which are important for lung branching
and morphogenesis [38]. In the mammary gland, MMP-2 is
important for ductal elongation whereas MMP-3 promotes
side branching [39,40]. Disruption of the MMP network by the
lack of ErbB3 could result in decreased ability of the ducts to
penetrate the surrounding stroma.
Despite the importance of branching, other abnormalities in
the ErbB3-null glands are likely also to contribute to the out-
growth/penetration defect. TEBs are epithelial structures
found at the end of a growing duct in the pubescent gland and
are responsible for growth and penetration of the normal epi-
thelial tree into the surrounding fat pad. TEBs are evident at
the tips of the advancing ducts until the edge of the fat pad is
reached, at which point they regress. In the ErbB3-null glands
there was an increase in the number of TEBs, probably due to
the increase in branching and consequently in the number of
ducts, but a decrease in the overall size of the TEBs. On a his-
tological level, the ErbB3-/- TEBs had a range of structural
abnormalities that could account for their small size (Figure 4).
Some of the TEBs were relatively normal in organization, with
an outer single layer of cap and myoepithelial cells marked by
P-cadherin expression, an inner multilayered body cell com-
partment marked by E-cadherin expression, and a central
cleared luminal space. A majority of the TEBs had some struc-
tural defect including large spaces between the cap/myoepi-
thelial cell layer and the body cell layer, and/or filled in luminal
spaces. The most severe TEB abnormalities were detected at
7 weeks after transplantation. The cap/myoepithelial cell com-
partment appeared to become multilayered and invaded or co-
inhabited the body cell compartment, which itself was numer-
ically diminished. This could occur through loss of normal com-
partmentalization boundaries, and even invasion of the inner
layers by the outer layer, perhaps accompanying loss of body
cells. Dysregulation of the P-cadherin or E-cadherin adhesion
systems could account for some of these structural abnormal-
ities, because they are important for maintaining the bounda-
ries as is netrin/neogenin signaling. It is possible that changes
in differentiation of progenitor cells alter the balance of these
populations.
With the information available, the most likely source of the
TEB aberrations is an increased rate of apoptosis. A change
in the normal balance between proliferation and apoptosis in
the TEBs of a pubertal mammary gland would affect the ability
of the epithelial tree to fill the fat pad. The proliferative cap cells
are typically located at the distal end of the TEB, whereas the
apoptotic cells are located in the inner body cell layer sur-
rounding the hollow lumen [32]. The pattern of apoptotic cells
in the TEBs suggests that apoptosis is responsible for clearing
of the lumen within the growing duct. In the ErbB3-null glands,
proliferation was not affected, but apoptosis as detected by
cleaved caspase 3 immunohistochemistry and the presence of
apoptotic figures in H&E-stained sections was increased in
comparison to ErbB3+ glands. ErbB3 has six binding sites for
the p85 adaptor subunit of PI3K and is strongly linked to pro-
survival signaling through the PI3K/Akt pathway. The uncou-
pling of ErbB3 from the PI3K/Akt pathway in ErbB3-null
outgrowths could result in the increase in apoptosis detected
in the TEBs. An increase in apoptosis would explain the large
number of cells in the normally cleared luminal space at 4
weeks after transplantation and then the apparent decrease in
body cells numbers in TEBs at 7 weeks in ErbB3-null glands.
The ErbB3-null pubescent mammary gland phenotype might
not be predicted based on earlier studies showing only limited
expression of ErbB3 in the pubescent gland. However, implan-
tation of the NRG1 in the pubescent mammary gland stimu-
lated epithelial growth [23]. Hence, one of the NRG receptors
ErbB3 and/or ErbB4 can function at this stage of mammary
development. Because loss of ErbB3 function, but not loss of
ErbB4 function, compromised pubescent mammary develop-
ment, it is likely that ErbB3 was activated by the implanted lig-
and. However, ErbB3 is devoid of kinase activity and requires
a heterodimerization partner for activation. Among the poten-
tial heterodimerization partners EGFR, ErbB2, and ErbB4,
only EGFR and ErbB2 are required for ductal outgrowth in the
pubescent mammary gland. EGFR is expressed in both the
epithelium and stroma, but it is only required in the stroma dur-
ing pubescent mouse mammary gland development [41].
Hence, ErbB2 may be the unique co-receptor, but EGFR and
ErbB4 may work redundantly with ErbB3.Breast Cancer Research    Vol 10 No 6    Jackson-Fisher et al.
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The epithelial null phenotype for ErbB2 [26] most closely
resembles the phenotype for ErbB3 null, consistent with the
importance of ErbB2/ErbB3 signaling at pubescence. ErbB2-
null mammary buds transplanted into wild-type fat pads
develop into ductal tree that grossly resembles the ErbB3-null
phenotype. However, in contrast to ErbB3 nulls, the defect
was present in the pubescent gland, but was not evident in
adult glands or pregnancy. ErbB2-null TEBs also had struc-
tural defects in the TEBs, characterized by a decrease in body
cell number, an increase in the presence of cap/myoepithelial-
like cells in the prelumenal compartment, and the presence of
large luminal spaces. The similar requirement for ErbB2 and
ErbB3 in the epithelium of the pubescent mammary gland
strongly implies that the ErbB2/ErbB3 heterodimer is impor-
tant in the epithelium at this stage in development.
The heterodimerization partner(s) dictates the range of ligands
capable of activating ErbB3 in the pubescent mammary gland.
Because ErbB2 does not bind soluble ligands, the ErbB2/
ErbB3 heterodimer would need to be activated by ligand-
bound ErbB3. However, because growth factors in this family
are activated by proteolysis, further work will be required to
determine the importance of these agonists in pubescent
mammary development. Knockout studies have shown that
NRG1 isoform α is required, but in adult maturation of the
mammary gland [28].
If ErbB3 is heterodimerized with EGFR, then other ligands
could be responsible for transactivation of ErbB3. Of the
known EGFR ligands, amphiregulin has been shown to be
important and upregulated during pubescent mammary gland
development [42,43]. With the mammary defects in amphireg-
ulin-knockout mice, EGFR is probably signaling in the epithe-
lium either as a homodimer or heterodimer with ErbB2 and/or
ErbB3 in the pubescent mouse mammary gland.
ErbB family members are over-expressed because of amplifi-
cation or have activating mutations in a variety of human can-
cers. Mutated EGFR has been found in a subset of NSCLCs,
and ERBB2 is amplified and over-expressed in up to 30% of
human breast cancers, which is associated with a poorer clin-
ical outcome. In both contexts, the ErbBs are validated thera-
peutic targets. ErbB3 may be quite important in governing the
signaling output of the activated ErbBs, initial response to
therapies, and in the development of drug resistance. For
example, some NSCLC patients with EGFR mutations with a
good clinical response to EGFR inhibitors gefitinib or erlotinib
initially, but later develop resistance. In one study, half of these
patients developed a second activating mutation, whereas the
other half had amplified MET, which encodes a receptor tyro-
sine kinase activated by hepatocyte growth factor [18] (for
review, see [19]). The NSCLC tumors escaped tyrosine kinase
inhibition because MET activates ErbB3 and the prosurvival
PI3K kinase pathway. In human breast cancer cells that over-
express ErbB2 and have also developed resistance to tyrosine
kinase inhibitor therapy, there is active PI3K/Akt via ErbB3 sig-
naling [15]. In summary, therapies that target ErbB tyrosine
kinase activities, kinase inactive ErbB3 and the downstream
PI3K/Akt signaling may evade inhibition. A better understand-
ing of ErbB3 in normal mammary gland signaling will reveal the
nature of endogenous regulators, and may be beneficial to
development of future directed therapies.
Conclusion
The ErbB3-/- mammary outgrowth defect was associated with
a decrease in the size of the TEBs, and increases in branch
density, in the number of terminal end buds, and in the number
of luminal spaces. Proliferation rates were not affected by the
lack of ErbB3, but there was a trend toward increased apop-
tosis in ErbB3-/- TEBs. Hence, endogenous ErbB3 regulates
morphogenesis of mammary epithelium, most likely through
impact on cell survival and other ErbB3-regulated processes.
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